In January of this year, President Barack Obama said that personalized medicine “gives us one of the greatest opportunities for new medical breakthroughs that we have ever seen.” We couldn’t agree more! In an effort to further educate representatives on Capitol Hill, our CEO, Michael Pellini, MD, participated in a lively expert discussion detailing how personalized medicine translates to improved health outcomes for patients and decreases costs for the health system as a whole.
The Personalized Medicine Coalition (PMC) organized the personalized medicine Hill briefing at the request of co-hosts, Sens. Amy Klobuchar (D-MN) and Orrin Hatch (R-UT) to discuss what personalized medicine means for patients and examine relevant policy issues. Topics included regulation and reimbursement and brought together a discussion provoking line-up of patients, healthcare providers and representatives from the biopharmaceutical and diagnostics industries.
We at Foundation Medicine strongly believe that comprehensive genomic profiling is an important step in informing treatment decisions, identifying relevant clinical trials and driving drug development for oncology-related personalized medicine. Foundation Medicine is focused on advancing personalized medicine for the betterment of patient care and hopes to rally further support from government, payors, regulatory authorities and policy makers to progress the effort.